New World Health Organization (WHO) guidelines have the potential to transform the TB treatment landscape with six-month standard. Read more from our statement on the WHO's Rapid Communication for drug-resistant #tuberculosis treatment: bit.ly/TBA-WHO-DR-TB #EndTB

Exciting paper on intrinsic antibiotic resistance factors for 9 antibiotics (7 against tuberculosis) and how inhibition of those can reverse acquired drug resistance Rock Lab 🧬🧫 Rockefeller University nature.com/articles/s4156…

We look for a highly motivated postdoc to join an interdisciplinary team working on the preclinical development of anti-tuberculosis compounds ERA4TB Project Universidad Zaragoza

Just out: World Health Organization (WHO) 2022 Global Tuberculosis Report. Tedros Adhanom Ghebreyesus “If the pandemic has taught us anything, it’s that with solidarity, determination, innovation and the equitable use of tools, we can overcome severe health threats. Let’s apply those lessons to TB” who.int/news/item/27-1…

Join us in spectacular A Coruña, Spain 🇪🇸, for the 3⃣1⃣st PAGE meeting between 27-30 June 2023! Make sure that you mark the following dates in your calendar! 👉Registration opens 23 January 09:00 CET 🗓️Abstract submission deadline 19 March 23:59 CET #PKPD #pharmacometrics #PBPK

Scientist from different disciplines can speak different languages. Let’s learn each others terms to correctly use them across our multidisciplinary work. Excellent example in ⁦⁦ASCPT Journal Family⁩ on describing pharmacometric models (multivariable!) ascpt.onlinelibrary.wiley.com/doi/full/10.10…

People with tuberculous meningitis are suffering from the most devastating form of TB. Many antibiotics don't reach the brain. Linezolid does get to the target site, which I'll present at the ASCPT Alexandria Poster Session this afternoon! Great to be back at the in-person ASCPT!

🎉We're thrilled to announce the newest publication from ERA4TB partners showing the benefits of standardized working in #tuberculosis #research Read it here: bit.ly/40FFvvR Co-lead author, Rob van Wijk, Rob van Wijk, explains why this work is so important.

Join us Thursday at 12pm ET for our TRAC Seminar "Translational predictions of phase 2 efficacy studies for antituberculosis drugs" by Rob van Wijk tbcenter.jhu.edu/event/trac-sem…

This week’s most viewed article: Current Causes of Death in Children and Adolescents in the United States nej.md/3Ez4ire #GunViolence

How do we Build the Global Pharmacometrics Community? What is the Pharmacometrics Africa program? Webinar at Wed 4th Oct at 10:00am EST/ 16:00pm CEST by the ASCPT Alexandria Global Health community. Registration (free for LMIC scientists) at bit.ly/45SGx9G

Why should you submit your late-breaking, encore, and trials-in-progress abstract? Because when you present your abstract at #ASCPT2024 you are connecting with colleagues and experts that can provide you with crucial feedback on your research: bit.ly/2O8TQMd

📢 We are delighted to announce our confirmed speakers . 📈 Stay tuned for more information . #RedIFCongress2024

Today marks an exciting day for UNITE4TB and the #TB community as a whole as we announce the start of our phase 2B/C clinical trial program, which has officially kicked off in Cape Town, South Africa. Find out more in our video: rb.gy/61yoo5, just launched